Aerovate Therapeutics, Inc. AVTE
Institutional shares held
32.4 Million
30.3K
calls
57.9K
puts
Total value of holdings
$86.7M
$81K
calls
$155K
puts
Market Cap
$65.5M
24,448,100
Shares Out.
Institutional ownership
132.35%
# of Institutions
85
We take great care to ensure that the data presented and summarized in this overview for Aerovate Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AVTE
View all-
Ra Capital Management, L.P. Boston, MA9.19MShares$24.6 Million0.48% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$10.1 Million0.69% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$6.01 Million1.35% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.82 Million1.32% of portfolio
-
Adar1 Capital Management, LLC Austin, TX1.46MShares$3.92 Million0.68% of portfolio
-
Braidwell LP Stamford, CT1.44MShares$3.86 Million0.22% of portfolio
-
Allostery Investments LP Stamford, CT1.42MShares$3.81 Million5.15% of portfolio
-
Logos Global Management LP San Francisco, CA1.4MShares$3.75 Million0.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.07MShares$2.86 Million0.0% of portfolio
-
Black Rock Inc. New York, NY983KShares$2.63 Million0.0% of portfolio
Latest Institutional Activity in AVTE
Top Purchases
Top Sells
About AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Transactions at AVTE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2025
|
Tom Frohlich Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+50.0%
|
$42,000
$7.4 P/Share
|
|
Apr 28
2025
|
Ra Capital Management, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
1,062,326
+45.2%
|
-
|
|
Aug 01
2024
|
Benjamin T Dake |
BUY
Exercise of conversion of derivative security
|
Direct |
1,507
+9.56%
|
$1,507
$1.74 P/Share
|
|
Jul 31
2024
|
Benjamin T Dake |
BUY
Exercise of conversion of derivative security
|
Direct |
11,454
+47.33%
|
$11,454
$1.74 P/Share
|
|
Jun 17
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
928,110
+10.52%
|
$928,110
$1.67 P/Share
|
|
Jun 14
2024
|
Marinus Verwijs CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,600
-100.0%
|
$265,000
$25.0 P/Share
|
|
Jun 14
2024
|
Marinus Verwijs CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,600
+50.0%
|
$148,400
$14.59 P/Share
|
|
Jun 14
2024
|
George A Eldridge |
SELL
Open market or private sale
|
Direct |
15,000
-74.92%
|
$375,000
$25.03 P/Share
|
|
Jun 14
2024
|
George A Eldridge |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+42.83%
|
$30,000
$2.14 P/Share
|
|
Jun 13
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,000
-51.72%
|
$144,000
$24.5 P/Share
|
|
Jun 13
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+34.09%
|
$12,000
$2.14 P/Share
|
|
May 17
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,000
-21.14%
|
$84,000
$21.47 P/Share
|
|
May 17
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+29.41%
|
$8,000
$2.14 P/Share
|
|
May 16
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-93.54%
|
$210,000
$21.72 P/Share
|
|
May 16
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.14 P/Share
|
|
May 02
2024
|
Marinus Verwijs CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,981
-100.0%
|
$41,601
$21.02 P/Share
|
|
May 01
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
11,357
-96.78%
|
$227,140
$20.37 P/Share
|
|
May 01
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.14 P/Share
|
|
Apr 17
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,000
-29.8%
|
$88,000
$22.82 P/Share
|
|
Apr 17
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+35.55%
|
$4,000
$1.74 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.04M
Shares
From
7
Insiders
| Other acquisition or disposition | 1.06M shares |
|---|---|
| Open market or private purchase | 934K shares |
| Exercise of conversion of derivative security | 44.6K shares |
Sell / Disposition
31.6K
Shares
From
3
Insiders
| Open market or private sale | 31.6K shares |
|---|